Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29014325 | 0.87 | RIPK1 (0.56) | SCN9ARIPK1BACE1 | |
| SCHEMBL30314212 | 0.87 | RIPK1 (0.56) | SCN9ARIPK1BACE1 | |
| SCHEMBL23900326 | 0.87 | RIPK1 (0.56) | SCN9ARIPK1BACE1 | |
| SCHEMBL12376317 | 0.77 | SCN9A (0.69) | SCN9ARIPK1NPY1R | |
| SCHEMBL5638220 | 0.77 | SCN9A (0.69) | SCN9ARIPK1NPY1R | |
| SCHEMBL12376364 | 0.77 | SCN9A (0.69) | SCN9ARIPK1NPY1R | |
| SCHEMBL25875348 | 0.77 | GAA (0.43) | SCN9ARIPK1BACE1 | |
| SCHEMBL23075140 | 0.76 | SCN9A (0.52) | SCN9ARIPK1BACE1NPY1R | |
| SCHEMBL14468801 | 0.76 | GAA (0.47) | SCN9ANPY1R | |
| SCHEMBL83962 | 0.76 | GAA (0.47) | SCN9ANPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | SCN9A 3587/4885RIPK1 1/4885BACE1 1815/4885 |
| US-20230227469-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | SCN9A 3587/4885RIPK1 1/4885BACE1 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.